ALTERITY THERAPEUTICS LIMITED - Announcements

Market Cap $31.47M Add to my watchlist

Healthcare Biotechnology

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company’s lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson’s disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Announcements

Filter Results

All Price Sensitive Only

ATH	2018 AGM Presentation		16/11/18	620.89KB	Share
ATH	Prana AGM Investor Conference Call		12/11/18	748.43KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/18	189.64KB	Share
ATH	Notice of Annual General Meeting/Proxy Form		17/10/18	857.17KB	Share
ATH	New data show potential for PBT434 to treat MSA	PRICE SENSITIVE	05/10/18	698.02KB	Share
ATH	Annual report 2018 on Form 20-F & XBRL data filed with SEC		03/09/18	665.22KB	Share
ATH	Form 20-F		03/09/18	2.26MB	Share
ATH	Preliminary Final Report	PRICE SENSITIVE	31/08/18	2.42MB	Share
ATH	Annual Report to shareholders	PRICE SENSITIVE	31/08/18	2.35MB	Share
ATH	Appendix 4G		31/08/18	132.83KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/18	262.22KB	Share
ATH	Appendix 3B and 708A Notice		13/07/18	248.28KB	Share
ATH	Prana to present PBT434 data at International Congress	PRICE SENSITIVE	09/07/18	751.56KB	Share
ATH	First Volunteers Dosed in Phase I Clinical Trial of PBT434	PRICE SENSITIVE	04/07/18	209.53KB	Share
ATH	Investor Presentation (amended)		27/06/18	3.17MB	Share
ATH	Investor Presentation - Treatment of Neurological Disorders		27/06/18	3.17MB	Share
ATH	Prana to commence Phase 1 clinical trial of PBT434	PRICE SENSITIVE	14/06/18	716.14KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	27/04/18	279.83KB	Share
ATH	Prana to Present at the B. Riley FBR Symposium in China		16/03/18	469.17KB	Share
ATH	PBT434 at the 6th International Multiple System Atrophy Conf	PRICE SENSITIVE	06/03/18	637.33KB	Share
ATH	Form 6-K		28/02/18	148.29KB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/18	275.48KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/18	698.63KB	Share
ATH	Appendix 3B		18/01/18	811.63KB	Share
ATH	Dr. David Stamler presenting at Biotech Showcase		08/01/18	465.33KB	Share
ATH	Investor Presentation - Treatment of Neurological Disorders		08/01/18	2.64MB	Share
ATH	Change of Director's Interest Notice		22/12/17	532.01KB	Share
ATH	Change of Director's Interest Notice		22/12/17	532.3KB	Share
ATH	Change of Director's Interest Notice		22/12/17	532.41KB	Share
ATH	Change of Director's Interest Notice		22/12/17	532.81KB	Share
ATH	Change of Director's Interest Notice		22/12/17	534.04KB	Share
ATH	Appendix 3B		19/12/17	811.92KB	Share
ATH	Prana receives $3 million R&D Tax Incentive Refund	PRICE SENSITIVE	19/12/17	609.71KB	Share
ATH	2017 AGM Results of Meeting		17/11/17	96.04KB	Share
ATH	AGM 2017 Presentation		17/11/17	1000.03KB	Share
ATH	Prana AGM Investor Conference Call		10/11/17	910.31KB	Share
ATH	Form 6-K		09/11/17	70.41KB	Share
ATH	Prospectus Supplement	PRICE SENSITIVE	09/11/17	148.88KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/17	697.57KB	Share
ATH	Notice of Meeting/ Proxy Form	PRICE SENSITIVE	13/10/17	12.69MB	Share
ATH	Form F-3	PRICE SENSITIVE	11/10/17	246.36KB	Share
ATH	Change of Address		25/09/17	619.5KB	Share
ATH	Annual Report filed on Form 20-F with SEC		06/09/17	599.49KB	Share
ATH	Form 20-F		01/09/17	821.99KB	Share
ATH	Appendix 4G		31/08/17	263.86KB	Share
ATH	Appendix 4E and Annual Report	PRICE SENSITIVE	31/08/17	2.09MB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/17	697.27KB	Share
ATH	Prana commences research collaboration with Takeda	PRICE SENSITIVE	18/07/17	618.4KB	Share
ATH	PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration	PRICE SENSITIVE	03/07/17	687.1KB	Share
ATH	Change of address		26/06/17	366.2KB	Share
ATH	Appendix 3B		07/06/17	815.52KB	Share
ATH	David Stamler appointed as CMO to lead Clinical Development		05/06/17	624.94KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	27/04/17	52.36KB	Share
ATH	PBT434 presented at 13th International AD/PD Conference	PRICE SENSITIVE	30/03/17	371.7KB	Share
ATH	Form 6-K		24/02/17	221.45KB	Share
ATH	Half Year Accounts	PRICE SENSITIVE	24/02/17	281.58KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/17	282.44KB	Share
ATH	Response to ASX Price Query	PRICE SENSITIVE	09/01/17	472.31KB	Share
ATH	Business Update	PRICE SENSITIVE	23/12/16	445.25KB	Share
ATH	Results of Meeting		17/11/16	61.84KB	Share
ATH	Prana AGM Investor Webcast Details		14/11/16	439.68KB	Share
ATH	Prana provides regulatory update for PBT2-PBT.AX	PRICE SENSITIVE	03/11/16	92.66KB	Share
ATH	Prana provides regulatory update for PBT2	PRICE SENSITIVE	03/11/16	92.66KB	Share
ATH	Prana announces $4.8 million R&D refund-PBT.AX	PRICE SENSITIVE	31/10/16	464.26KB	Share
ATH	Appendix 4C - quarterly-PBT.AX	PRICE SENSITIVE	31/10/16	281.69KB	Share
ATH	New Reach2HD data presented at American Neurological Assoc.-PBT.AX	PRICE SENSITIVE	18/10/16	97.57KB	Share
ATH	Notice of Annual General Meeting/Proxy Form-PBT.AX		14/10/16	8.57MB	Share
ATH	Prospectus Supplement-PBT.AX		14/10/16	195.7KB	Share
ATH	Form 6-K-PBT.AX		14/10/16	253.08KB	Share
ATH	Annual Report filed on Form 20-F with SEC-PBT.AX		05/10/16	438.86KB	Share
ATH	Form 20F-PBT.AX		05/10/16	877.71KB	Share
ATH	Appendix 4G-PBT.AX		30/09/16	119.22KB	Share
ATH	Annual Report to shareholders-PBT.AX		30/09/16	2.75MB	Share
ATH	Preliminary Final Report-PBT.AX	PRICE SENSITIVE	28/08/16	685.9KB	Share
ATH	Preliminary Final Report-PBT.AX	PRICE SENSITIVE	26/08/16	685.9KB	Share
ATH	Response to ASX Price Query-PBT.AX	PRICE SENSITIVE	10/08/16	673.18KB	Share
ATH	Prana Alzheimer's disease data at world leading conference-PBT.AX		27/07/16	77.8KB	Share
ATH	Appendix 4C - quarterly-PBT.AX	PRICE SENSITIVE	27/07/16	262.02KB	Share
ATH	Huntington Disease trial analysis to feature at Conference-PBT.AX		22/06/16	375.97KB	Share
ATH	Response to ASX Price Query-PBT.AX	PRICE SENSITIVE	14/06/16	525.35KB	Share
ATH	Prana announces $6.5 million R&D refund-PBT.AX	PRICE SENSITIVE	09/05/16	370.48KB	Share
ATH	Appendix 4C - quarterly-PBT.AX	PRICE SENSITIVE	29/04/16	193.05KB	Share
ATH	Prana presents at World Orphan Drug Congress-PBT.AX		22/04/16	3.04MB	Share
ATH	Prana Regains Compliance With NASDAQ Listing Requirements-PBT.AX		11/04/16	91.86KB	Share
ATH	Prana completes ratio change on NASDAQ		24/03/16	389.63KB	Share
ATH	S&P DJ Indices Announces March Quarterly Review		11/03/16	337.28KB	Share
ATH	ADR Ratio Change		09/03/16	91.3KB	Share
ATH	Form 6-K		26/02/16	169.69KB	Share
ATH	Appendix 4D Half Yearly Report and Accounts	PRICE SENSITIVE	25/02/16	1.18MB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/16	195.2KB	Share
ATH	Results of Meeting		13/11/15	65.62KB	Share
ATH	AGM Presentation		13/11/15	785.59KB	Share
ATH	Prana AGM webcast details		10/11/15	365.21KB	Share
ATH	NASDAQ Deficiency Notice Received		06/11/15	357.23KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/15	192.77KB	Share
ATH	Notice of Annual General Meeting/Proxy Form		12/10/15	578.47KB	Share
ATH	Prana reports FY15 financial results		27/08/15	401.87KB	Share
ATH	Form 20-F		27/08/15	875.46KB	Share
ATH	Appendix 4G		26/08/15	217.43KB	Share
ATH	Appendix 4E and Annual Report 2015	PRICE SENSITIVE	26/08/15	8.18MB	Share

ATH 2018 AGM Presentation
16/11/18		620.89KB	Share
ATH Prana AGM Investor Conference Call
12/11/18		748.43KB	Share
ATH Appendix 4C - quarterly
30/10/18	PRICE SENSITIVE	189.64KB	Share
ATH Notice of Annual General Meeting/Proxy Form
17/10/18		857.17KB	Share
ATH New data show potential for PBT434 to treat MSA
05/10/18	PRICE SENSITIVE	698.02KB	Share
ATH Annual report 2018 on Form 20-F & XBRL data filed with SEC
03/09/18		665.22KB	Share
ATH Form 20-F
03/09/18		2.26MB	Share
ATH Preliminary Final Report
31/08/18	PRICE SENSITIVE	2.42MB	Share
ATH Annual Report to shareholders
31/08/18	PRICE SENSITIVE	2.35MB	Share
ATH Appendix 4G
31/08/18		132.83KB	Share
ATH Appendix 4C - quarterly
31/07/18	PRICE SENSITIVE	262.22KB	Share
ATH Appendix 3B and 708A Notice
13/07/18		248.28KB	Share
ATH Prana to present PBT434 data at International Congress
09/07/18	PRICE SENSITIVE	751.56KB	Share
ATH First Volunteers Dosed in Phase I Clinical Trial of PBT434
04/07/18	PRICE SENSITIVE	209.53KB	Share
ATH Investor Presentation (amended)
27/06/18		3.17MB	Share
ATH Investor Presentation - Treatment of Neurological Disorders
27/06/18		3.17MB	Share
ATH Prana to commence Phase 1 clinical trial of PBT434
14/06/18	PRICE SENSITIVE	716.14KB	Share
ATH Appendix 4C - quarterly
27/04/18	PRICE SENSITIVE	279.83KB	Share
ATH Prana to Present at the B. Riley FBR Symposium in China
16/03/18		469.17KB	Share
ATH PBT434 at the 6th International Multiple System Atrophy Conf
06/03/18	PRICE SENSITIVE	637.33KB	Share
ATH Form 6-K
28/02/18		148.29KB	Share
ATH Half Yearly Report and Accounts
28/02/18	PRICE SENSITIVE	275.48KB	Share
ATH Appendix 4C - quarterly
31/01/18	PRICE SENSITIVE	698.63KB	Share
ATH Appendix 3B
18/01/18		811.63KB	Share
ATH Dr. David Stamler presenting at Biotech Showcase
08/01/18		465.33KB	Share
ATH Investor Presentation - Treatment of Neurological Disorders
08/01/18		2.64MB	Share
ATH Change of Director's Interest Notice
22/12/17		532.01KB	Share
ATH Change of Director's Interest Notice
22/12/17		532.3KB	Share
ATH Change of Director's Interest Notice
22/12/17		532.41KB	Share
ATH Change of Director's Interest Notice
22/12/17		532.81KB	Share
ATH Change of Director's Interest Notice
22/12/17		534.04KB	Share
ATH Appendix 3B
19/12/17		811.92KB	Share
ATH Prana receives $3 million R&D Tax Incentive Refund
19/12/17	PRICE SENSITIVE	609.71KB	Share
ATH 2017 AGM Results of Meeting
17/11/17		96.04KB	Share
ATH AGM 2017 Presentation
17/11/17		1000.03KB	Share
ATH Prana AGM Investor Conference Call
10/11/17		910.31KB	Share
ATH Form 6-K
09/11/17		70.41KB	Share
ATH Prospectus Supplement
09/11/17	PRICE SENSITIVE	148.88KB	Share
ATH Appendix 4C - quarterly
30/10/17	PRICE SENSITIVE	697.57KB	Share
ATH Notice of Meeting/ Proxy Form
13/10/17	PRICE SENSITIVE	12.69MB	Share
ATH Form F-3
11/10/17	PRICE SENSITIVE	246.36KB	Share
ATH Change of Address
25/09/17		619.5KB	Share
ATH Annual Report filed on Form 20-F with SEC
06/09/17		599.49KB	Share
ATH Form 20-F
01/09/17		821.99KB	Share
ATH Appendix 4G
31/08/17		263.86KB	Share
ATH Appendix 4E and Annual Report
31/08/17	PRICE SENSITIVE	2.09MB	Share
ATH Appendix 4C - quarterly
27/07/17	PRICE SENSITIVE	697.27KB	Share
ATH Prana commences research collaboration with Takeda
18/07/17	PRICE SENSITIVE	618.4KB	Share
ATH PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration
03/07/17	PRICE SENSITIVE	687.1KB	Share
ATH Change of address
26/06/17		366.2KB	Share
ATH Appendix 3B
07/06/17		815.52KB	Share
ATH David Stamler appointed as CMO to lead Clinical Development
05/06/17		624.94KB	Share
ATH Appendix 4C - quarterly
27/04/17	PRICE SENSITIVE	52.36KB	Share
ATH PBT434 presented at 13th International AD/PD Conference
30/03/17	PRICE SENSITIVE	371.7KB	Share
ATH Form 6-K
24/02/17		221.45KB	Share
ATH Half Year Accounts
24/02/17	PRICE SENSITIVE	281.58KB	Share
ATH Appendix 4C - quarterly
30/01/17	PRICE SENSITIVE	282.44KB	Share
ATH Response to ASX Price Query
09/01/17	PRICE SENSITIVE	472.31KB	Share
ATH Business Update
23/12/16	PRICE SENSITIVE	445.25KB	Share
ATH Results of Meeting
17/11/16		61.84KB	Share
ATH Prana AGM Investor Webcast Details
14/11/16		439.68KB	Share
ATH Prana provides regulatory update for PBT2-PBT.AX
03/11/16	PRICE SENSITIVE	92.66KB	Share
ATH Prana provides regulatory update for PBT2
03/11/16	PRICE SENSITIVE	92.66KB	Share
ATH Prana announces $4.8 million R&D refund-PBT.AX
31/10/16	PRICE SENSITIVE	464.26KB	Share
ATH Appendix 4C - quarterly-PBT.AX
31/10/16	PRICE SENSITIVE	281.69KB	Share
ATH New Reach2HD data presented at American Neurological Assoc.-PBT.AX
18/10/16	PRICE SENSITIVE	97.57KB	Share
ATH Notice of Annual General Meeting/Proxy Form-PBT.AX
14/10/16		8.57MB	Share
ATH Prospectus Supplement-PBT.AX
14/10/16		195.7KB	Share
ATH Form 6-K-PBT.AX
14/10/16		253.08KB	Share
ATH Annual Report filed on Form 20-F with SEC-PBT.AX
05/10/16		438.86KB	Share
ATH Form 20F-PBT.AX
05/10/16		877.71KB	Share
ATH Appendix 4G-PBT.AX
30/09/16		119.22KB	Share
ATH Annual Report to shareholders-PBT.AX
30/09/16		2.75MB	Share
ATH Preliminary Final Report-PBT.AX
28/08/16	PRICE SENSITIVE	685.9KB	Share
ATH Preliminary Final Report-PBT.AX
26/08/16	PRICE SENSITIVE	685.9KB	Share
ATH Response to ASX Price Query-PBT.AX
10/08/16	PRICE SENSITIVE	673.18KB	Share
ATH Prana Alzheimer's disease data at world leading conference-PBT.AX
27/07/16		77.8KB	Share
ATH Appendix 4C - quarterly-PBT.AX
27/07/16	PRICE SENSITIVE	262.02KB	Share
ATH Huntington Disease trial analysis to feature at Conference-PBT.AX
22/06/16		375.97KB	Share
ATH Response to ASX Price Query-PBT.AX
14/06/16	PRICE SENSITIVE	525.35KB	Share
ATH Prana announces $6.5 million R&D refund-PBT.AX
09/05/16	PRICE SENSITIVE	370.48KB	Share
ATH Appendix 4C - quarterly-PBT.AX
29/04/16	PRICE SENSITIVE	193.05KB	Share
ATH Prana presents at World Orphan Drug Congress-PBT.AX
22/04/16		3.04MB	Share
ATH Prana Regains Compliance With NASDAQ Listing Requirements-PBT.AX
11/04/16		91.86KB	Share
ATH Prana completes ratio change on NASDAQ
24/03/16		389.63KB	Share
ATH S&P DJ Indices Announces March Quarterly Review
11/03/16		337.28KB	Share
ATH ADR Ratio Change
09/03/16		91.3KB	Share
ATH Form 6-K
26/02/16		169.69KB	Share
ATH Appendix 4D Half Yearly Report and Accounts
25/02/16	PRICE SENSITIVE	1.18MB	Share
ATH Appendix 4C - quarterly
29/01/16	PRICE SENSITIVE	195.2KB	Share
ATH Results of Meeting
13/11/15		65.62KB	Share
ATH AGM Presentation
13/11/15		785.59KB	Share
ATH Prana AGM webcast details
10/11/15		365.21KB	Share
ATH NASDAQ Deficiency Notice Received
06/11/15		357.23KB	Share
ATH Appendix 4C - quarterly
30/10/15	PRICE SENSITIVE	192.77KB	Share
ATH Notice of Annual General Meeting/Proxy Form
12/10/15		578.47KB	Share
ATH Prana reports FY15 financial results
27/08/15		401.87KB	Share
ATH Form 20-F
27/08/15		875.46KB	Share
ATH Appendix 4G
26/08/15		217.43KB	Share
ATH Appendix 4E and Annual Report 2015
26/08/15	PRICE SENSITIVE	8.18MB	Share

REFRESH

First 3 4 5 6 7

(20min delay)
Last 0.6¢		Change 0.000(0.00%)		Mkt cap ! $31.47M

Open	High	Low	Value	Volume
0.6¢	0.6¢	0.6¢	$9.573K	1.633M

Buyers (Bids)

No.	Vol.	Price($)
70	66663606	0.5¢

Sellers (Offers)

Price($)	Vol.	No.
0.6¢	12189391	9

View Market Depth

No.	Vol.	Price($)
70	66663606	0.005
53	59859382	0.004
49	47623315	0.003
17	33693014	0.002
12	93870101	0.001

Price($)	Vol.	No.
0.006	12189391	9
0.007	21612749	17
0.008	16761310	22
0.009	11788078	12
0.010	2540594	8

Last trade - 16.10pm 08/05/2024 (20 minute delay)


Last 0.6¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
0.6¢	0.6¢	0.6¢	363313
Last updated 15.59pm 08/05/2024 ?

ATH (ASX) Chart

ALTERITY THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories